ACRO Biomedical Co

ACRO Biomedical Co Share Buybacks

The Share Buybacks of ACRO Biomedical Co (6748.TWO) as of Oct 21, 2026 is 11.97 M TWD. In the previous year, Share Buybacks was 112.58 M TWD — a change of -89.37% (lower).

Share Buybacks

11.97 MTWD

YoY

-89.37%

Last updated:

Share Buybacks of ACRO Biomedical Co is 2019 11.97 M TWD. Share Buybacks of ACRO Biomedical Co was 2018 112.58 M TWD. It decreases by -89.37% lower compared to the previous year.

The ACRO Biomedical Co Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2018
112.58 M TWD
Jan 1, 2019
11.97 M TWD
The ACRO Biomedical Co Share Buybacks history
YEARShare BuybacksYoY
11.97 MTWD-89.37%
112.58 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Share Buybacks of ACRO Biomedical Co is 11.97 M TWD in 2019.

Share Buybacks of ACRO Biomedical Co changed from 112.58 M TWD to 11.97 M TWD, representing a -89.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's ACRO Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co